Skip to main content
Publications
Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, Lopez C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-58. doi: 10.1016/S2468-1253(21)00110-2
Phiri K, Hallas J, Linder M, Margulia A, Suehs B, Arana A, Bahmanyar S, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Sahlertz Kristiansen N, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Poster presented at the American Urological Association 2020 Conference (Conference cancelled); May 2020. Washington, DC. [abstract] J Urol. 2020 Apr; 203(Supplement 4):e910-1. doi: 10.1097/JU.0000000000000931.010
Tell-Marti G, Puig-Butille JA, Potrony M, Plana E, Badenas C, Antonell A, Sanchez-Valle R, Molinuevo JL, Lleo A, Alcolea D, Fortea J, Fernandez-Santiago R, Clarimon J, Llado A, Puig S. A common variant in the MC1R gene (p.V92M) is associated with Alzheimer's disease risk. J Alzheimers Dis. 2017 Feb 3;56(3):1065-74. doi: 10.3233/JAD-161113